Dr. Aimen Arij

What Evidence Shows NAD+ Supplements Impact Aging and Support Cellular Health?

Nicotinamide adenine dinucleotide, universally abbreviated NAD+, is one of the most heavily studied molecules in the biology of aging. It sits at…

Retatrutide for Type 2 Diabetes: A1C and Weight Results

In TRIUMPH-2, the phase 3 trial in 1,152 adults with type 2 diabetes and obesity or overweight, retatrutide cut A1C by up…

What Evidence Supports the Use of BPC-157 for Musculoskeletal Healing?

Few research peptides have attracted as much attention from athletes, biohackers, and injured weekend warriors as BPC-157, a synthetic 15-amino-acid sequence widely…

What Does Research Say About the Benefits of TB-500 for Tissue Repair and Healing?

TB-500 is one of the most talked-about compounds in the “recovery peptide” conversation, routinely described in forums and vendor copy as a…

What Evidence Supports the Grow-H Peptide Blend Based on Current Research?

Short answer: Grow-H has never been tested as a blend in any controlled trial. It is a vendor name for a two-peptide…

Glow Peptide and Skin Brightening: What the Evidence Shows

There is no human trial of the Glow blend for brightening or anti-aging — not one.11 And there is a second problem…

PT-141 (Bremelanotide): How It Works, Results and Side Effects

The short answer. PT-141 (bremelanotide) works on the brain, not on blood flow. It activates melanocortin receptors in the central nervous system…

Does AOD-9604 Burn Fat Without Losing Lean Muscle?

No — not in humans, and the reason is specific. When AOD-9604 was finally taken into an adequately powered, randomized, placebo-controlled obesity…

How Much Weight Do You Lose on Orforglipron? ATTAIN Trial Results

In the pivotal ATTAIN-1 trial, adults with obesity taking orforglipron 36 mg lost an average of 12.4 percent of their body weight —…

How Do Semaglutide Trials Demonstrate Its Role in Long-Term Obesity Treatment?

Across the STEP program, semaglutide 2.4 mg weekly produced roughly 15% mean weight loss at 68 weeks; in STEP 1, 86.4% of…